Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Compound 4 (PF-04971729) belongs to a new class of potent and selective sodium-dependent glucose cotransporter 2 inhibitors incorporating a unique dioxa-bicyclo[3.2.1]octane (bridged ketal) ring system. In this paper we present the design, synthesis, preclinical evaluation, and human dose predictions related to 4. This compound demonstrated robust urinary glucose excretion in rats and an excellent preclinical safety profile. It is currently in phase 2 clinical trials and is being evaluated for the treatment of type 2 diabetes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/jm200049r | DOI Listing |
Publication Analysis
Top Keywords
unique dioxa-bicyclo[321]octane
8
sodium-dependent glucose
8
glucose cotransporter
8
cotransporter inhibitors
8
discovery clinical
4
clinical candidate
4
candidate structurally
4
structurally unique
4
dioxa-bicyclo[321]octane class
4
class sodium-dependent
4